IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.275
AS - Asia 11.102
EU - Europa 9.307
SA - Sud America 1.413
AF - Africa 170
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 32
Totale 36.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.991
CN - Cina 6.518
SG - Singapore 2.211
IE - Irlanda 2.204
UA - Ucraina 1.559
HK - Hong Kong 1.428
FI - Finlandia 1.176
BR - Brasile 1.167
DE - Germania 1.075
RU - Federazione Russa 871
SE - Svezia 750
IT - Italia 649
GB - Regno Unito 456
VN - Vietnam 348
FR - Francia 216
CA - Canada 167
IN - India 131
AR - Argentina 101
MX - Messico 71
BD - Bangladesh 65
PL - Polonia 58
NL - Olanda 56
ZA - Sudafrica 56
JP - Giappone 52
IQ - Iraq 46
ES - Italia 44
AT - Austria 43
TR - Turchia 41
BE - Belgio 36
ID - Indonesia 30
AU - Australia 29
IR - Iran 29
PK - Pakistan 29
EC - Ecuador 28
CO - Colombia 26
UZ - Uzbekistan 24
CZ - Repubblica Ceca 20
EU - Europa 20
LT - Lituania 20
CL - Cile 19
KE - Kenya 19
SA - Arabia Saudita 18
VE - Venezuela 18
MU - Mauritius 17
MA - Marocco 16
PY - Paraguay 16
EG - Egitto 15
KR - Corea 14
PA - Panama 14
IL - Israele 13
JO - Giordania 13
AE - Emirati Arabi Uniti 12
UY - Uruguay 12
BO - Bolivia 11
DK - Danimarca 11
RO - Romania 10
AZ - Azerbaigian 9
PE - Perù 9
BG - Bulgaria 7
JM - Giamaica 7
KZ - Kazakistan 7
MY - Malesia 7
TN - Tunisia 7
CR - Costa Rica 6
DZ - Algeria 6
NP - Nepal 6
SK - Slovacchia (Repubblica Slovacca) 6
SN - Senegal 6
XK - ???statistics.table.value.countryCode.XK??? 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AL - Albania 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
LV - Lettonia 5
OM - Oman 5
PT - Portogallo 5
RS - Serbia 5
ET - Etiopia 4
GE - Georgia 4
LA - Repubblica Popolare Democratica del Laos 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
PH - Filippine 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BH - Bahrain 3
BW - Botswana 3
GA - Gabon 3
GR - Grecia 3
GY - Guiana 3
HN - Honduras 3
HU - Ungheria 3
KW - Kuwait 3
LB - Libano 3
MD - Moldavia 3
ML - Mali 3
MN - Mongolia 3
NI - Nicaragua 3
BA - Bosnia-Erzegovina 2
Totale 36.294
Salva come PNG Salva come JPEG
Città #
Chandler 2.219
Dublin 2.201
Jacksonville 1.998
Nanjing 1.557
Hong Kong 1.419
Dallas 1.194
Ashburn 1.024
Singapore 880
Beijing 792
Boardman 780
Nanchang 615
Princeton 515
Lawrence 494
Wilmington 489
Hebei 462
Shenyang 456
Changsha 411
Jiaxing 372
Los Angeles 349
Medford 349
Helsinki 256
Hangzhou 249
Tianjin 237
New York 221
Ann Arbor 206
Buffalo 196
Redondo Beach 150
Milan 144
Ho Chi Minh City 143
Munich 132
Moscow 131
Shanghai 116
Woodbridge 111
São Paulo 97
Norwalk 96
Toronto 89
Seattle 77
Verona 76
Pavia 72
Lauterbourg 70
Hanoi 69
The Dalles 69
Turku 62
Jinan 61
Nuremberg 58
Falls Church 54
Brooklyn 53
Chicago 51
Guangzhou 51
Warsaw 50
Falkenstein 48
Zhengzhou 48
Tokyo 46
San Francisco 44
Washington 44
Fairfield 42
Kunming 40
Santa Clara 40
Houston 38
Stockholm 38
Des Moines 37
Ningbo 37
Montreal 36
Brussels 34
Orem 33
Rome 33
Chennai 32
Belo Horizonte 31
London 31
Taizhou 31
Johannesburg 29
Atlanta 28
Boston 28
Denver 28
Council Bluffs 27
Rio de Janeiro 26
Mexico City 25
Columbus 23
Manchester 23
Phoenix 23
Curitiba 22
Haiphong 21
Poplar 21
Tappahannock 21
Tashkent 21
Brasília 20
Vienna 19
Guarulhos 18
Ankara 17
Auburn Hills 17
Charlotte 17
Frankfurt am Main 17
Lanzhou 17
Baghdad 16
Goiânia 16
Dhaka 15
Florence 15
Nairobi 15
Porto Alegre 15
San Jose 15
Totale 23.401
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 162
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 161
A B-cell lymphoproliferative disorder 148
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 144
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 137
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 134
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 130
A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data 130
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 128
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 128
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 127
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 126
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 125
A case of persistent eosinophilia 123
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 123
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 122
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 122
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 122
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 122
Blast phase of essential thrombocythemia: A single center study. 120
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. 120
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 118
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 117
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 117
Anemia associata ad endocrinopatie. 114
[Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons] 114
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 113
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 113
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 113
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 112
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 112
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 111
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 111
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 111
Classification and prognostic evaluation of myelodysplastic syndromes 110
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 110
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 109
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 109
A chronic lymphoproliferative disorder 108
A gain-of-function mutation of JAK2 in myeloproliferative disorders 108
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 106
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 105
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 105
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 103
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 103
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 102
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 102
JAK2 (V617F) mutation in healthy individuals 101
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 101
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 100
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 100
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 100
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 100
Clinical significance of somatic mutation in unexplained blood cytopenia 100
Juvenile chronic myelogenous leukemia: in vitro characterization before and after allogeneic bone marrow transplantation 100
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 100
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 99
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 99
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 98
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 98
"In vitro" megakaryocytopoiesis in patients with HIV-related thrombocytopenic purpura. 98
A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. 97
Clinical and biological implications of driver mutations in myelodysplastic syndromes 97
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 96
Further concerns about the medical risks of blood doping. 96
Pincered red cells and hereditary spherocytosis. 96
Revised international prognostic scoring system for myelodysplastic syndromes 96
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 95
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 95
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 95
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 95
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 95
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 95
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 94
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 94
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 94
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 93
A novel deletion of the L-ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. 93
A patient-oriented approach to treatment of myelodysplastic syndromes. 92
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. 91
Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells 91
Ittero. 90
Cerebrospinal fluid ferritin in human disease. 90
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 90
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 90
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 90
Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: An in vivo confocal study 90
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 89
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 89
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 89
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 89
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 89
Translational pathophysiology: a novel molecular mechanism of human disease 88
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 88
Leukemia risk models in primary myelofibrosis: an International Working Group study. 88
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 88
Classification of anaemia on the basis of ferrokinetic parameters. 88
The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms 88
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 88
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 87
Totale 10.582
Salva come PNG Salva come JPEG
Categoria #
all - tutte 165.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.745
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.885 0 0 0 0 0 378 31 453 126 439 374 84
2021/20222.188 32 8 65 39 101 130 40 119 120 93 340 1.101
2022/20236.356 743 374 47 520 634 706 3 403 2.629 33 164 100
2023/20242.266 253 446 95 204 219 618 65 137 15 53 60 101
2024/20255.893 156 567 173 188 109 216 239 540 1.230 224 677 1.574
2025/20267.775 1.044 1.234 1.656 1.792 1.504 545 0 0 0 0 0 0
Totale 36.899